0 Items - $0.00
Categories
A to Z

Alternative structural projections:

8-pHPT-2'-O-Me-cAMP

8- (4- Hydroxyphenylthio)- 2'- O- methyladenosine- 3', 5'- cyclic monophosphate , sodium salt ( 8-pHPT-2'-O-Me-cAMP )
Potent Epac agonist
Cat. No.: H 010
    
CAS No.: [612513-15-2]
Shipping: ambient
Product Name Price (net) Qty
Cat. No.: H 010-05
Unit: 5 µmol / ~2.4 mg
$187.00
For other salt forms please inquire. Specific activator of the exchange protein activated by cyclic AMP (Epac) or cAMP-GEF, respectively, which does not activate protein kinase A. High lipophilicity and membrane permeability, as well as increased PDE stability. Detailed technical information and updated references available. References: Christensen et al., J. Biol. Chem., 278, 35394 - 3540 (2003); Holz et al., J. Physiol., 577, 5 – 15 (2006).
Cat. No. H 010
Patent Information Protected by patent n° EP 02077219.0 and foreign equivalents, exclusively licensed to BIOLOG LSI for research purposes only
CAS number [612513-15-2]
Purity > 98% HPLC
Salt form Sodium
Storage temperature -20°C / -4°F
Molecular formula C₁₇H₁₇N₅O₇PS · Na
Molecular weight [g/mol] 489,4
Modifications 8-cAMP, 2'-cAMP
Target Epac Activator
Lipophilicity 2.32
Absorption max [nm] 282
Molar extinction coefficient ε [L·mol⁻¹·cm⁻¹] 16000
  • 1. Enyeart J. A., Liu H.Enyeart J. J., Am. J. Physiol. Endocrinol. Metab., 301, 941 - 954 (2011), "8-Phenylthio-adenines Stimulate the Expression of Steroid Hydroxylases, Cav3.2 Ca2+ Channels, and Cortisol Synthesis by a cAMP-independent Mechanism"
  • 2. Holz G. G., Chepurny O. G.Schwede F., Cell. Signal., 20, 10 - 20 (2008), "Epac-selective cAMP Analogs: New Tools with which to Evaluate the Signal Transduction Properties of cAMP-regulated Guanine Nucleotide Exchange Factors"
  • 3. Schmidt M., Sand C., Jakobs K. H., Michel M. C.Weernink P. A. O., Curr. Opin. Pharmacol., 7, 1 - 8 (2007), "Epac and the Cardiovascular System"
  • 4. Yano N., Suzuki D., Endoh M., Zhao T. C., Padbury J. F.Tseng Y. T., J. Biol. Chem., 282, 18819 - 18830 (2007), "A Novel Phosphoinosite 3-Kinase-dependent Pathway for Angiotensin II/AT-1 Receptor-mediated Induction of Collagen Synthesis in MES-13 Mesangial Cells"
  • 5. Kooijman R., Gerlo S.Verdood P., Patent WO 2007/006544, 0, 0 - 0 (2007), "Cyclic Adenosine Monophosphate Compounds for the Treatment of Immune-Related Disorders"
  • 6. Holz G. G., Kang G., Harbeck M., Roe M. W.Chepurny O. G., J. Physiol.- London, 577, 5 - 15 (2006), "Cell Physiology of cAMP Sensor Epac"
  • 7. Genieser H.-G., Bos J. L., Christensen A. E., Doeskeland S. O., Havemann U., Manzau U., Rehmann H.Schwede F., Poster #THP016 Montreal, 12, 0 - 0 (2004), "Analogues of Cyclic AMP to Distinguish Between PKA and Epac"
  • 8. Christensen A. E., Selheim F., de Rooij J., Dremier S., Schwede F., Dao K. K., Martinez A., Maenhaut C., Bos J. L., Genieser H.-G.Doeskeland S. O., J. Biol. Chem., 278, 35394 - 35402 (2003), "cAMP Analog Mapping of Epac1 and cAMP-Kinase. Discriminating Analogs Demonstrate that Epac and cAMP-Kinase Act Synergistically to Promote PC-12 Cell Neurite Extension"